39 results about "Ventricular muscle" patented technology

Methods of implanting an annuloplasty ring to correct maladies of the mitral annulus that not only reshapes the annulus but also reconfigures the adjacent left ventricular muscle wall. A posterior portion of the ring rises or bows upward from adjacent sides to pull the posterior aspect of the native annulus farther up than its original, healthy shape. In doing so, the ring also pulls the ventricular wall upward which helps mitigate some of the effects of congestive heart failure. Further, one or both of the posterior and anterior portions of the ring may also bow inward. The methods include securing the annuloplasty ring with the anterior portion against the annulus anterior aspect and the posterior portion against the annulus posterior aspect so that the ring posterior portion elevates, and may also pull radially inward, the annulus posterior aspect and corrects the mitral regurgitation.

The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell sequencing are also provided. The invention provides in vitro methods of the separation of NRP1+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated NRP1+ ventricular progenitor cells are also provided. Methods of in vivo use of NRP1+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the NRP1+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

The invention provides a method for differentiating as ventricular muscle cells by in-vitro induced pluripotent stem cells. The method comprises the following steps: through maintaining, amplifying, and culturing pluripotent stem cells in vitro, in the metaphase of pluripotent stem cell cardiac muscle differentiation, namely the differentiation stage from mesoblastema or cardiac muscle precursor cells to the cardiac muscle cells, adding a substance for directly or indirectly activating an Smad1 / 5 / 8 signal channel to a culture medium, and enabling the stem cells to be directionally differentiated as the ventricular muscle cells. The ventricular muscle cells with the biology activity and function can be successfully obtained by using the method. A regulation mechanism in the differentiation process from the cardiac muscle precursor cells to the ventricular muscle cells is presented, and the human ventricular muscle cells obtained by the differentiation can be extensively applied for the myocardial infarction therapy by the cell transplantation and the cardiac toxicology analysis and the development of cardiac related drugs.

The invention provides a method for recording an Nav 1.5 sodium channel current by separating cavy ventricular muscle cells. The method comprises two steps of separating a single cavy ventricular muscle cell and recording the Nav 1.5 sodium channel current. According to the method, the yield rate and the survival rate of the separated cavy ventricular muscle cells are enhanced by improvement of a perfusate and a storage way, and the success rate and the stability of an experiment are increased by the prolonging of the stable time of the cell. The separated cavy ventricular muscle cell has a normal ion channel function and the method is suitable to research on a ventricular muscle physiological characteristic by a patch clamp technique; the experiment operation is easy to master, and the method for acutely separating the ventricular muscle cells is simple and efficient.

The present invention provides LIFR and FGFR3 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ LIFR+ ventricular progenitor cells and / or Islet 1+ / FGFR3+ ventricular progenitor cells and / or Islet 1+ / LIFR+ / FGFR3+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated LIFR+ and / or FGFR3+ ventricular progenitor cells are also provided. Methods of in vivo use of LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

The present invention provides Jagged 1 and Frizzled 4 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ Jagged 1+ ventricular progenitor cells and / or Islet 1+ / Frizzled 4+ ventricular progenitor cells and / or Islet 1+ / Jagged 1+ / Frizzled 4+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated Jagged 1+ and / or Frizzled 4+ventricular progenitor cells are also provided. Methods of in vivo use of Jagged 1+ and / or Frizzled 4+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the Jagged 1+ and / or Frizzled 4+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

The present invention provides LIFR and FGFR3 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ LIFR+ ventricular progenitor cells and / or Islet 1+ / FGFR3+ ventricular progenitor cells and / or Islet 1+ / LIFR+ / FGFR3+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated LIFR+ and / or FGFR3+ ventricular progenitor cells are also provided. Methods of in vivo use of LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell sequencing are also provided. The invention provides in vitro methods of the separation of NRP1+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated NRP1+ ventricular progenitor cells are also provided. Methods of in vivo use of NRP1+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the NRP1+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.

The invention provides a preparation method of Korean mondshood root total alkaloids and applications in preparing a slow sodium-ion passage blocking agent and preparing drugs for resisting arrhythmia. Both the Korean mondshood root total alkaloids and the guanfu base I are provided to have an effect for inhibiting slow sodium current of ventricular muscles of cavies. The invention particularly relates to an application of guanfu base VIIII in preparing a drug-metabolizing enzyme inhibitor. The invention also provides an application of guanfu base VIIII in preparing a slow sodium-ion passage blocking agent.

The invention provides a preparation method of total alkaloids of radix aconiti coreani as well as an application of the total alkaloids of radix aconiti coreani in preparing a slow sodium ion channel blocker and an antiarrhythmic medicine. Researches show that both the total alkaloids of radix aconiti coreani and Guanfu A hydrochlorate have an inhibiting effect on a slow sodium current of the ventricular muscle of a guinea pig. The invention particularly relates to an application of the Guanfu base I in preparing enzyme inhibitors for drug metabolism. The invention further provides an application of the Guanfu base A in preparing the slow sodium ion channel blocker.

The present invention relates to the application of miRNA in the treatment of myocardial hypertrophy. Specifically, the miRNA is hsa-miR-15a-5p / hsa-miR-16-5p, and its nucleotide sequences are respectively as SEQ ID NO.1 and SEQ ID NO.1. Shown in ID NO.2. The cardiac hypertrophy refers to a pathophysiological process mainly characterized by thickening of the ventricular muscle and narrowing of the chamber caused by the overload of the heart caused by heredity, hypertension, myocardial infarction, valvular disease and the like. The present invention also relates to the application of the complex loaded with hsa-miR-15a-5p / hsa-miR-16-5p in the preparation of medicine for treating myocardial hypertrophy, the complex being CHO-PGEA-nucleic acid complex.

The invention belongs to the technical field of medical electronics, and particularly discloses a defibrillator provided with an extended H bridge circuit output stage and a high-voltage discharge method based on an output stage circuit. The output stage circuit comprises an energy storage capacitor, an inductance coil, current sensors and a plurality of control switches, wherein the control switches are connected mutually to form an extended H bridge circuit switch with three vertical arm bridge circuits and two transverse arm bridge circuits. The high-voltage discharge method comprises the steps that electric energy in the capacitor and induction electric energy in the inductance coil are discharged at a high voltage onto a body of a patient by a defibrillation electrode in a biphase sawtooth waveform mode, so as to terminate fibrillation of a ventricular muscle and implement timely rescue of the patient via the output stage of the defibrillator according to a series of preset bridge circuit switch combinations and control strategies. The defibrillator and the high-voltage discharge method can lower the requirement on a high voltage characteristic of a discharge bridge circuit, individual and accurately-controlled defibrillation electric energy is provided for the patient, the success rate of electric shock defibrillation on a heart is increased, and injures to a cardiac muscle in a defibrillation process are reduced.